ストックスクリーナーアプリを入手
104.31
3.28%
3.31
アフターアワーズ：
101.75
-2.56
-2.45%
前日終値:
$101.00
開ける：
$101.26
24時間の取引高:
765.47K
Relative Volume:
1.01
時価総額：
$25.08B
収益：
$3.13B
当期純損益:
$-381.72M
株価収益率:
-65.02
EPS:
-1.6042
ネットキャッシュフロー:
$-2.15B
1週間 パフォーマンス:
+0.78%
1か月 パフォーマンス:
-4.53%
6か月 パフォーマンス:
+6.02%
1年 パフォーマンス:
+5.08%
1日の値動き範囲:
$100.66
$104.48
1週間の範囲:
$99.90
$114.89
52週間の値動き範囲:
$81.20
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
BNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
104.31 | 24.28B | 3.13B | -381.72M | -2.15B | -1.6042 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.37 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.58 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.20 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
763.52 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.67 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech SE Sponsored ADR $BNTX Shares Sold by Fred Alger Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Millennium Management LLC - MarketBeat
Edmond DE Rothschild Holding S.A. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Amundi Reduces Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baird Financial Group Inc. Has $1.13 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Alyeska Investment Group L.P. Has $6.83 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults - Benzinga
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - Ariva
Nomura Holdings Inc. Makes New $2.83 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Canada Pension Plan Investment Board - MarketBeat
ADAR1 Capital Management LLC Acquires New Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday - Benzinga
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
B. Metzler seel. Sohn & Co. AG Has $1.46 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $135.80 Average Target Price from Analysts - MarketBeat
Jump Financial LLC Makes New $1.98 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
APG Asset Management N.V. Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
T. Rowe Price Investment Management Inc. Purchases 32,818 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
BioNTech SE Sponsored ADR $BNTX Shares Acquired by HighTower Advisors LLC - Defense World
Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - The Globe and Mail
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
BioNTech’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - The Globe and Mail
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks
BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings - Defense World
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - MSN
US Bancorp DE Cuts Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s New Study on Breast Cancer Treatment: A Potential Game-Changer? - The Globe and Mail
BioNTech (NASDAQ:BNTX) Price Target Lowered to $136.00 at HC Wainwright - Defense World
BioNTech’s BNT113 Trial: A Potential Game-Changer in Head and Neck Cancer Treatment - TipRanks
BioNTech’s Latest Clinical Study: A New Hope for Advanced Breast Cancer Treatment - The Globe and Mail
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks
BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer - The Globe and Mail
BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech ADR Earns RS Rating Upgrade - Investor's Business Daily
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.10%
3.17%
大文字化:
|
ボリューム (24 時間):